| Description |
1 online resource (xi, 233 pages) |
| Series |
Cancer etiology, diagnosis, and treatments |
|
Cancer etiology, diagnosis, and treatments.
|
| Contents |
TARGETED THERAPIES IN CANCER; TARGETED THERAPIES IN CANCER; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter 1: Innovation in the Biopharmaceutical Pipeline; Abstract; Introduction; Drug Discovery and Development Process; Discovery and Preclinical Testing; Clinical Testing in Human Subjects; Regulatory Review and Approval; Post-Approval Research and Monitoring; References; Chapter 2: The Diversity of Targeted Cancer Drugs Recently Approved by the FDA; Abstract; Introduction; 1) Tyrosine Kinase (TK) Inhibitors (TKIs) |
|
2) Serine/Threonine Kinase Inhibitors (STKIs)3) Monoclonal Antibodies (MAbs); 4) Decoy Vascular Endothelial Growth Factor Receptor; 5) Immunomodulatory Agents; 7) Antimetabolites; 8) Enzymes; 9) Histone Deacetylase (HDAC) Inhibitors; 10) Proteasome Inhibitors; 11) Hedgehog Pathway Inhibitor; 12) Protein Translation Inhibitor; 13) Hormone (Androgen Deprivation) Therapy; 14) Microtubule Targeting Agents; 15) Autologous Cellular Immunotherapy; 16) Radiopharmaceutical Compound; References; Chapter 3: Chronological List of Targeted Cancer Drugs Approved by the FDA; Abstract; Introduction |
|
ReferenceChaper 4: Targeted Therapies: Detailed Description; Abstract; Introduction; Rituximab; Trastuzumab; Imatinib; Alemtuzumab; Ibritumomab; Gefitinib; Tositumomab; Azacitidine; Pemetrexed; Cetuximab; Bevacizumab; Erlotinib; Nelarabine; Sorafenib; Pegaspargase; Lenalidomide; Sunitinib; Dasatinib; Panitumumab; Vorinostat; Bortezomib; Decitabine; Lapatinib; Temsirolimus; Ixabepilone; Nilotinib; Degarelix; Everolimus; Pralatrexate; Pazopanib; Ofatumumab; Romidepsin; Cabazitaxel; Sipuleucel-T; Eribulin; Denosumab; Ipilimumab; Vandetanib; Abiraterone; Vemurafenib; Brentuximab; Crizotinib |
|
Asparaginase Erwinia chrysanthemiAxitinib; Vismodegib; Pertuzumab; Carfilzomib; Ziv-aflibercept; Enzalutamide; Bosutinib; Regorafenib; Omacetaxine; Cabozantinib; Ponatinib; Pomalidomide; Ado-trastuzumab Emtansine; Radium Ra223; Trametinib; Dabrafenib; Afatinib; Obinutuzumab; Ibrutinib; Ramucirumab; Ceritinib; Chapter 5: Targeted Therapy for Chronic Lymphocytic Leukemia (CLL); Abstract; Introduction; Rituximab; Rituximab As a Single Agent; Chemoimmunotherapy with Rituximab; Alemtuzumab; Ofatumumab; Ofatumumab and Chlorambucil; Obinutuzumab; Ibrutinib; Conclusion; References |
|
Chapter 6: Targeted Therapy for HER-2-Positive Breast CancerAbstract; Introduction; Trastuzumab; Lapatinib; Approved for HER-2-Overexpressing Breast Cancer; Approved for Hormone-Positive and HER-2-Positive Advanced Breast Cancer; Pertuzumab; Ado-Trastuzumab Emtansine; Conclusion; References; Chapter 7: Targeted Therapy for Metastatic Breast Cancer: Varia; Abstract; Introduction; Ixabepilone; Eribulin; Everolimus; Conclusion; References; Chapter 8: Targeted Therapy for Chronic Myelogenous Leukemia (CML); Abstract; Introduction; Imatinib; Imatinib and Resistance; Nilotinib; Dasatinib; Bosutinib |
| Summary |
Since the year 2000, exciting developments in cancer therapy have occurred. For decades in the 20th century, the hallmark of medical treatment for cancer had been cytotoxic chemotherapy, with drugs targeting rapidly dividing cells, including cancer cells but also certain normal tissues. As a result, many patients experienced the ""classic"" toxicities of alopecia, gastrointestinal symptoms and/or myelosuppression. In the last years, however, clinical research has been strongly occupied with the identification of mutations and aberrations concerning molecular pathways in cancer and their altera |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record |
| Subject |
Cancer -- Treatment.
|
|
Drug targeting.
|
|
Drug Delivery Systems
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Cancer -- Treatment
|
|
Drug targeting
|
| Form |
Electronic book
|
| ISBN |
9781633216877 |
|
163321687X |
|
